公开(公告)号：US20140315919A1

公开(公告)日：2014-10-23

申请号：US14321100

申请日：2014-07-01

申请人： The University of Mississippi ,  I'Universite Catholique de Louvain

发明人： Christopher McCurdy ,  Christophe Mesangeau ,  Sanju Narayanan ,  Rae Reiko Matsumoto ,  Jacques Henri Poupaert

IPC分类号： C07D277/70 ,  C07D491/107 ,  C07D417/06

CPC分类号： C07D277/70 ,  A61K51/0455 ,  A61K51/0459 ,  A61K51/0468 ,  C07D235/26 ,  C07D263/58 ,  C07D277/68 ,  C07D401/06 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D491/10 ,  C07D491/107

摘要： A compound useful for treating subjects in need of therapy involving sigma receptors or for alleviation of affects resulting from drug abuse having the general formula I in which R1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle such as, for example, radicals of optionally substituted piperidines, optionally substituted piperazines, optionally substituted tetrahydropyridines, optionally substituted azepanes, tertiary amines (cyclic or acyclic), isoindoline-1,3-dione, or optionally substituted tetrahydroisoquinolones (aromatically substituted): R2,3,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Y can be either CH, CH2, O, S, OCH2, N—R, N—Ar, C—R, C—Ar; Z can be either H, O, S, S—R or NR. R groups can be either H, aryls, alkyls, or cycloalkyls; “n” can be 1 to 5 carbons in length and stereoisomers, functional analogs, and pharmaceutically acceptable salts thereof and wherein the moiety bridging R1 and N can be optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene and where the alkylene group can include an inserted C3-C5 cycloalkyl group, aromatic and heterocyclic group.

摘要翻译： 可用于治疗需要治疗涉及σ受体的受试者或用于缓解由具有通式I的药物滥用引起的影响的化合物的化合物，其中R 1可以是任选取代的C-4至C-7N-杂环的基团， 任选取代的四氢吡啶，任选取代的氮杂环庚烷，叔胺（环状或非环状），异二氢吲哚-1,3-二酮或任选取代的四氢异喹诺酮（芳族取代的）：R2， 3,4,5,6可以各自独立地为下列部分中的任何一种或组合：氰基，硝基，酰基，烷基，酰氨基，叠氮基，异硫氰酸酯，异氰酸酯任选取代的苯胺基，卤素，醚，磺酰胺，硫代酰基，硝基，芳族 ，杂环，烯属，乙炔，氘或氚; Y可以是CH，CH 2，O，S，OCH 2，N-R，N-Ar，C-R，C-Ar; Z可以是H，O，S，S-R或NR。 R基团可以是H，芳基，烷基或环烷基; “n”可以是长度为1至5个碳原子，立体异构体，功能类似物和其药学上可接受的盐，其中桥接R 1和N的部分可以是任选取代的亚烷基，任选取代的亚烯基或任选取代的亚炔基，并且其中亚烷基可以包括 插入的C 3 -C 5环烷基，芳族和杂环基。